Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CytomX Therapeutics (CTMX) Goodwill & Intangibles (2016 - 2025)

CytomX Therapeutics' Goodwill & Intangibles history spans 12 years, with the latest figure at $1.4 million for Q4 2025.

  • For Q4 2025, Goodwill & Intangibles fell 9.46% year-over-year to $1.4 million; the TTM value through Dec 2025 reached $1.4 million, down 9.46%, while the annual FY2025 figure was $1.4 million, 9.46% down from the prior year.
  • Goodwill & Intangibles reached $1.4 million in Q4 2025 per CTMX's latest filing, down from $1.4 million in the prior quarter.
  • In the past five years, Goodwill & Intangibles ranged from a high of $2.1 million in Q1 2021 to a low of $1.4 million in Q4 2025.
  • Average Goodwill & Intangibles over 5 years is $1.7 million, with a median of $1.7 million recorded in 2023.
  • Peak YoY movement for Goodwill & Intangibles: decreased 6.56% in 2021, then dropped 9.46% in 2025.
  • A 5-year view of Goodwill & Intangibles shows it stood at $2.0 million in 2021, then fell by 7.41% to $1.8 million in 2022, then fell by 8.0% to $1.7 million in 2023, then decreased by 8.7% to $1.5 million in 2024, then dropped by 9.46% to $1.4 million in 2025.
  • Per Business Quant, the three most recent readings for CTMX's Goodwill & Intangibles are $1.4 million (Q4 2025), $1.4 million (Q3 2025), and $1.5 million (Q2 2025).